Aromatase and breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 102, Issue 1-5 SPEC. ISS., 2006, Pages 97-102

  Brodie, A ^a   Sabnis, G ^a   Jelovac, D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; NITRILES; OVARIECTOMY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TRIAZOLES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 33751005025     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.09.002     Document Type: Article

References (13)

1. Yue W., Zhou D.J., Chen S., and Brodie A.M.H. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 54 (1994) 5092-5095
2. Yue W., Wang J., Savinov A., and Brodie A. Effect of aromatase inhibitors on the growth of mammary tumors in a nude mouse model. Cancer Res. 55 (1995) 3073-3077
3. Zhou D., Pompon D., and Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 50 (1990) 6949-6954
4. Lu Q., Wang J., Liu Y., Long B., and Brodie A. The effects of aromatase and antiestrogens in the nude mouse model. Breast Cancer Res. Treat. 50 (1998) 63-71
5. Lu Q., Liu Y., Long B.J., Grigoryev D., Gimbel M., and Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res. Treat. 57 (1999) 183-192
6. Long B.J., Jelovac D., Handratta V., Thiantanawat A., MacPherson N., Ragaz J., and Brodie A.M. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in breast cancer model. J. Natl. Cancer Inst. 96 6 (2004) 456-465
7. Long B.J., Jelovac D., Thiantanawat A., and Brodie A.M. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin. Cancer Res. 8 (2002) 2378-2388
8. Jelovac D., Sabnis G., Long B.J., Goloubeva O.G., and Brodie A.M.H. Activation of MAPK in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 65 (2005) 5380-5389
9. Pinheiro J.C., and Bates D.M. Mixed-Effects Models in S and S-Plus (2000), Springer-Verlag, New York, NY pp. 21-45, 174-196
10. Dunnett C.W. A multiple comparisons procedure for comparing several treatments with control. J. Am. Stat. Assoc. 50 (1955) 1096-1121
11. Scheffe H. A method of judging all contrasts in the analysis of variance. Biometrica 40 (1959) 87-104
12. Baum M., Buzdar A.U., Cuzick J., Forbes J., Houghton J., Klijn J.G.M., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359 (2002) 2131-2139
13. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092